Feldan Therapeutics partners with TransBIOTech on NSERC-funded project
Feldan Therapeutics partners with TransBIOTech on NSERC-funded project to accelerate development of innovative intra-lesional treatments
Quebec City, QC, March 12, 2026 – Feldan Therapeutics (“Feldan”), a clinical-stage biotechnology company specializing in the development of intracellular delivery-based therapies, today announced, in partnership with TransBIOTech, that it has been awarded a grant of CAD 450,000. This applied research and development (ARD) funding is awarded under the College and Community Innovation (CCI) program, administered by the Natural Sciences and Engineering Research Council of Canada (NSERC), in collaboration with the Social Sciences and Humanities Research Council (SSHRC) and the Canadian Institutes of Health Research (CIHR).
This non-dilutive funding will support Feldan's development of new therapeutic approaches targeting tumor lesions through intralesional injections over a three-year period. TransBIOTech will conduct the in vivo experiments necessary to advance this work.
As part of this initiative, Feldan continues to leverage its proprietary intracellular delivery platform, the Feldan Shuttle, which enables the design of various therapies, including targeted intralesional approaches for tumor and fibrotic lesions. By advancing Shuttle-based therapeutic candidates, the company aims to offer promising new therapeutic approaches for patients, while strengthening Canada's position in cutting-edge biomedical research. The partnership with TransBIOTech reinforces Feldan's ability to translate its technology into concrete clinical solutions.
This initiative builds on the company's expertise and ongoing development efforts, including its Phase 1/2a clinical trial evaluating FLD-103, a non-surgical treatment for basal cell carcinoma, the most common form of skin cancer. The work at Feldan will be led by Nancy Messier, Vice President, Drug Discovery, and her team.
"Our team is proud to receive this support from NSERC and thanks TransBIOTech, a partner in this initiative, for its contribution to the advancement of our work," said Dr. François-Thomas Michaud, CEO of Feldan Therapeutics. "This grant highlights the potential of our intracellular delivery platform and contributes to the advancement of our pipeline of therapeutic candidates. By leveraging our expertise in intralesional approaches, we continue to develop differentiated treatment strategies aimed at improving patient outcomes."
TransBIOTech is a Canadian research center that supports biotechnology companies in the development of innovative therapies through flexible, high-quality preclinical research services. TransBIOTech has the expertise and infrastructure necessary to successfully carry out all aspects of this research project. The work will be co-led by Dr. Frédéric Couture, principal investigator and head of TransBIOTech's pharmaceutical sciences department, and Dr. Carole-Ann Huppé, principal investigator specializing in immunology. The project will benefit from the support of TransBIOTech's highly qualified technical teams in its preclinical animal care facilities and biology and immunology laboratories, ensuring the rigorous execution of the experiments. Together, this multidisciplinary expertise enables TransBIOTech to generate robust preclinical data and support its partners in advancing promising therapies toward clinical development.
"Supporting Feldan Therapeutics in the development of their innovative therapies via the Feldan Shuttle for nearly ten years has been extremely rewarding," said Dr. Frédéric Couture, principal investigator and head of preclinical pharmacology at TransBIOTech. "Our team is proud to support Feldan in this new project, which will strengthen our expertise in evaluating new delivery platforms targeting solid tumors, while generating key data to advance this promising therapeutic approach."
As Canada's primary federal agency for funding research in the natural sciences and engineering, NSERC supports collaborations that drive innovation and economic growth. Programs such as the CCI strengthen research capacity and help accelerate the development of new treatments for unmet medical needs.
About Feldan
Feldan is a clinical-stage biotechnology company specializing in the development of drugs based on intracellular delivery. Feldan has developed the Feldan Shuttle, a proprietary peptide-based technology that enables safe, rapid, and efficient local delivery of antisense oligonucleotides (ASOs) inside cells. This technology paves the way for a new generation of treatments by providing access to otherwise inaccessible intracellular targets.
Feldan's pipeline focuses on diseases affecting the skin and lungs. The company is currently conducting a Phase 1/2a clinical trial of FLD-103, a non-surgical treatment for basal cell carcinoma (BCC). To provide patients with new treatments that can significantly improve their lives, Feldan is advancing FLD-201, an inhaled therapy for mucus-obstructive lung diseases such as non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, which is currently in preclinical development. The company is also continuing to optimize its technology for broader therapeutic applications.
For more information: www.feldan.com
About TransBIOTech
TransBIOTech, a College Center for Technology Transfer (CCTT) affiliated with Cégep de Lévis (QC, Canada), is a non-profit organization specializing in biotechnology. Since 1999, TransBIOTech has been providing expert support for drug development by offering services in pharmacology, cellular and molecular biology, biochemistry, pharmacokinetics, and toxicology. TransBIOTech researchers leverage their expertise and advanced methodologies to evaluate the mechanism of action, efficacy, and safety of therapeutic candidates at various stages of preclinical development.
